证券日报网讯9月3日晚间，海正药业（600267）发布公告称，公司将于2025年9月10日召开2025年第一 次临时股东大会。本次股东大会将审议《关于取消监事会并修订 <公司章程> 的议案》《关于制定、修 订、废止部分公司治理制度的议案》等多项议案。 ...

Market Performance - The Artemisinin concept index rose by 0.17%, ranking third among concept sectors, with three stocks increasing in value, including Baihua Medicine which hit the daily limit, and Fosun Pharma and China Resources Sanjiu which rose by 0.39% and 0.05% respectively [1] - The top gainers in the Artemisinin sector were Baihua Medicine, Fosun Pharma, and China Resources Sanjiu, while the biggest losers included Delong Huineng, New Harmony, and Zhejiang Medicine, which fell by 3.33%, 1.18%, and 1.17% respectively [1] Capital Flow - The Artemisinin concept sector experienced a net outflow of 58 million yuan in main capital, with Baihua Medicine receiving the highest net inflow of 109 million yuan, followed by China Resources Sanjiu and Zhejiang Medicine with net inflows of 14.16 million yuan and 5.79 million yuan respectively [2] - The net inflow ratios for Baihua Medicine, China Resources Sanjiu, and Zhejiang Medicine were 29.47%, 5.98%, and 2.65% respectively, indicating strong interest in these stocks [3] Stock Performance Details - Baihua Medicine had a daily increase of 10.03% with a turnover rate of 9.48% and a main capital flow of 108.91 million yuan, leading the sector [3] - Other notable stocks included China Resources Sanjiu with a slight increase of 0.05% and a turnover rate of 1.18%, and Zhejiang Medicine which decreased by 1.17% with a turnover rate of 1.48% [3][4]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 10, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [1][6] Voting Procedures - Online voting will be conducted through the Shanghai Stock Exchange's shareholder meeting online voting system, available from 9:15 AM to 3:00 PM on the day of the meeting [2][4] - Shareholders can vote via the trading system during specific trading hours [2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Agenda Items - The meeting will review several proposals, including amendments to the company's management systems and governance rules [3][7] - The proposal to revise the remuneration management system for directors and senior management has already been approved by the board [3] Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on September 4, 2025, are eligible to attend [5] - Registration for attendance must be completed by September 8, 2025, with specific documentation required [5][6] Additional Services - The company will provide a reminder service for shareholders to ensure participation in the meeting through SMS notifications [6]

浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 二○二五年九月十日 浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 会议议程 时间：2025 年 9 月 10 日（周三）下午 14：00，会期半天 地点：浙江海正药业股份有限公司（以下简称"公司"）会议室（台州市椒江区外沙 路 46 号） 主要议程： 上述议案已经公司第十届董事会第六次会议审议通过，具体内容详见 2025 年 8 月 26 日的《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 （www.sse.com.cn）。 三、股东及其授权代表发言及答疑 四、对上述各议案进行投票表决 五、统计有效表决票 2 1、总监票组织监票小组 2、股东及股东代表投票 一、宣布大会开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于取消监事会并修订《公司章程》的议案 | | 2.00 | 关于制定、修订、废止部分公司治理制度的议案 | | 2.01 | 关于修订 ...

证券代码：600267 证券简称：海正药业 公告编号：2025-52 号 浙江海正药业股份有限公司 浙江海正药业股份有限公司（以下简称"公司"）于2025年8月26日在《中 国证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2025年第一次临时股东大会的通 知》（公告编号：临2025-49号）。本次股东大会采用现场和网络投票相结合的 方式召开，现发布本次临时股东大会提示性公告。 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会，经第十届董事会第六次会议召开。 关于召开2025年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 10 日 14 点 00 分 召开地点：浙江海正药业股份有限公 ...

Core Viewpoint - The companion animal business of leading animal health companies in China, such as Hai Zheng Dong Bao, Rui Pu Sheng Wu, and Jin He Sheng Wu, has shown significant growth, driven by product innovation and channel expansion, indicating a shift towards the companion animal market amid the rising "pet economy" [1][2]. Group 1: Company Performance - Rui Pu Sheng Wu's pet business achieved a revenue of 415 million yuan, a year-on-year increase of 17.94%, with the pet supply chain revenue reaching 376 million yuan, up 18.49% [1]. - Hai Zheng Dong Bao's pet business grew over 60%, with expectations that pet business will account for over 50% of its total revenue by 2025 [2]. - Jin He Sheng Wu is actively advancing its pet health business, currently offering 15 pet products, including 8 health products and 1 rabies vaccine [2]. Group 2: Product Innovation - Rui Pu Sheng Wu focuses on technological research and development, holding 115 new veterinary drug registration certificates, including 17 for pet products [3]. - Hai Zheng Dong Bao emphasizes the optimization and upgrading of pet medicines, with products like Xi Bei An being the only compliant compound for cat deworming [3]. - Jin He Sheng Wu has made significant progress in pet vaccine research, recently obtaining a patent for a dual-subunit vaccine for feline infectious respiratory disease and feline panleukopenia [3]. Group 3: Sales Expansion - Rui Pu Sheng Wu has established a nationwide pet medical supply chain service network, reaching 8,400 pet hospitals and 3,500 pet stores, with ongoing expansion into new regional markets [3]. - Hai Zheng Dong Bao is enhancing its online self-operated e-commerce capabilities, achieving over 100 million yuan in sales during the first half of the year, with a significant increase in orders during the "618" shopping festival [3]. - Jin He Sheng Wu is leveraging AI technology to create a digital channel through its pet app "Ai Chong Yi," which integrates service and sales, enhancing user engagement and sales opportunities [4].

（文章来源：证券日报） 证券日报网讯 9月1日晚间，海正药业发布公告称，2025年8月，公司未回购股份。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 5 月 5 | 12 | 日~2026 | 年 | 月 | 11 | 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 5,535,000股 | | | | | | | | 累计已回购股数占总股本比例 | 0.46% | | | | | | | | 累计已回购金额 | 50,891,385.00元 | | | | | | | | 实际回购价格区间 | 8.92元/股~9.40元/股 | | | | | | | 一 ...

每经头条（nbdtoutiao）——个人消费贷贴息明日开闸！贷30万元最多可享贴息3000元，一文读懂→ （记者 张喜威） 截至发稿，海正药业市值为131亿元。 每经AI快讯，海正药业（SH 600267，收盘价：10.92元）9月1日晚间发布公告称，截至2025年8月月 底，公司已累计回购股份约554万股，占公司总股本的比例为0.46%，购买的最高价为9.4元/股、最低价 为8.92元/股，已支付的总金额约为5089万元。 2024年1至12月份，海正药业的营业收入构成为：医药生产占比58.46%，药品销售占比39.29%，其他行 业占比1.94%，其他业务占比0.23%，CMO/CDMO/CRO业务占比0.08%。 ...

格隆汇9月1日丨海正药业(600267.SH)公布，截至2025年8月月底，公司已累计回购股份553.5万股，占公 司总股本的比例为0.46%，购买的最高价为9.40元/股、最低价为8.92元/股，已支付的总金额为5089.14万 元（不含交易费用）。 ...